Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Fukuoka University currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are being handled by 2 distinct examiners, indicating that each pending matter is under the review of a different individual. Furthermore, the prosecution is split across 2 distinct art units, which suggests that the university's current patent applications cover diverse sub-sectors within the broader biotechnology field.
The busiest examiner identified in the data is MOSS, NATALIE M, who is responsible for 1 busiest examiner pending action. Given that there are 2 pending office actions in total, MOSS, NATALIE M handles 1 of the active matters. This distribution between pending actions and examiners means that the university must manage 2 separate prosecution tracks simultaneously.
Practitioners should note the degree of dispersion relative to the number of active cases. With 2 pending office actions, 2 distinct examiners, and 2 distinct art units, there is no overlap in the personnel or the specific administrative groups reviewing the work. Success in the Biotechnology & Pharmaceuticals area for these specific filings will depend on successfully navigating the distinct requirements of both art units and the individual styles of the 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSS, NATALIE M | 1 | 30.8% | +17.1% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754196 | OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | VANHORN, ABIGAIL LOUISE | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277278 | CELL SHEET SUPPORT, CELL SHEET LAMINATE AND METHOD FOR PRODUCING SAME | MOSS, NATALIE M | 3d overdue |
| 17754196 | OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | VANHORN, ABIGAIL LOUISE | 33d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277278 | CELL SHEET SUPPORT, CELL SHEET LAMINATE AND METHOD FOR PRODUCING SAME | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 3d overdue | Pending | Aug 15, 2023 |
| 17754196 | OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | VANHORN, ABIGAIL LOUISE | 1636 | §102§103Other | Final Rejection | 33d | Pending | Mar 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial